# Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

> **NCT04851119** · PHASE1,PHASE2 · RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 147 (estimated)

## Conditions studied

- Colorectal Carcinoma
- Endometrial Carcinoma
- Melanoma
- Neuroblastoma
- Ovarian Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Recurrent Desmoid Fibromatosis
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Refractory Desmoid Fibromatosis
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Hepatocellular Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Solid Pseudopapillary Neoplasm of the Pancreas
- Wilms Tumor

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Dual X-ray Absorptiometry
- **DRUG:** Tegavivint
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT04851119
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-08
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04851119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04851119, "Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04851119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*